Claims for Patent: 8,486,991
✉ Email this page to a colleague
Summary for Patent: 8,486,991
Title: | Enantiomerically pure phosphoindoles as HIV inhibitors |
Abstract: | 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds. |
Inventor(s): | Storer; Richard (Folkestone, GB), Alexandre; Francois-Rene (Montpellier, FR), Dousson; Cyril (Canet, FR), Moussa; Adel M. (Burlington, MA), Bridges; Edward (Lewisburg, WV), Stewart; Alistair (Somerville, MA), Wang; Jing Yang (Acton, MA), Mayes; Benjamin Alexander (Boston, MA) |
Assignee: | Idenix Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 13/152,018 |
Patent Claims: | 1. A method of treating an HIV infection comprising administering to a subject in need thereof an effective amount of a pure compound of the following formula: ##STR00082##
or a pharmaceutically acceptable salt thereof, wherein the method further comprises administering the compound to the subject in combination or alternation with at least a second anti-HIV agent.
2. The method of claim 1, wherein the compound is enantiomerically pure. 3. The method of claim 1, wherein the compound is in a pharmaceutically acceptable oral dosage form. 4. The method of claim 3, wherein the oral dosage form is a capsule or tablet. 5. The method of claim 1, wherein the second anti-HIV agent is a protease inhibitor, a nucleoside or nucleotide reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a fixed dose combination, an entry inhibitor, a CCR5 co-receptor antagonist, a maturation inhibitor, or an integrase inhibitor. 6. The method of claim 5 wherein the second anti-HIV agent is amprenavir, tipranavir, indinavir, saquinavir, lopinavir, ritronavir, fosamprenavir, darunavir, atazanavir, nelfinavir, lamivudine, emtricitabine, abacavir, zalcitabine, zidovudine, tenofovir, didanosine, stavudine, delavirdine, efavirenz, nevirapine, Atripla, Combivir, Trizivir, Truvada, maraviroc, enfuvirtide, brecanivir, amdoxovir, apricitabine, elvucitabine, Etravirine, Rilpivirine, Calanolide A, Aplaviroc, Vicriviroc, Bevirimat, Elvitegravir, or raltegravir. 7. The method of claim 1, wherein the method further comprises administering the compound to the subject in combination or alternation with an anti-HBV agent. 8. The method of claim 7, wherein the anti-HBV agent is entecavir, lamivudine, interferon alfa-2b, peginterferon alfa-2a, adefovir dipivoxil, telbivudine, emtricitibine, clevudine, tenofovir, valtorcitabine, amdoxovir, remofovir, or racivir. 9. The method of claim 1, wherein the compound is administered orally. 10. The method of claim 9, wherein the compound is administered orally once per day. 11. The method of claim 1, wherein the compound is administered in combination with a second compound effective for the treatment or prevention of HCV infection in the subject. 12. A method of treating an HIV infection comprising administering to a subject in need thereof an effective amount of a pure compound of the following formula: ##STR00083## or a pharmaceutically acceptable salt thereof, wherein the method further comprises administering the compound to the subject in combination or alternation with at least a second anti-HIV agent. 13. The method of claim 12, wherein the compound is enantiomerically pure. 14. The method of claim 12, wherein the compound is in a pharmaceutically acceptable oral dosage form. 15. The method of claim 14, wherein the oral dosage form is a capsule or tablet. 16. The method of claim 12, wherein the second anti-HIV agent is a protease inhibitor, a nucleoside or nucleotide reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a fixed dose combination, an entry inhibitor, a CCR5 co-receptor antagonist, a maturation inhibitor, or an integrase inhibitor. 17. The method of claim 16 wherein the second anti-HIV agent is amprenavir, tipranavir, indinavir, saquinavir, lopinavir, ritronavir, fosamprenavir, darunavir, atazanavir, nelfinavir, lamivudine, emtricitabine, abacavir, zalcitabine, zidovudine, tenofovir, didanosine, stavudine, delavirdine, efavirenz, nevirapine, Atripla, Combivir, Trizivir, Truvada, maraviroc, enfuvirtide, brecanivir, amdoxovir, apricitabine, elvucitabine, Etravirine, Rilpivirine, Calanolide A, Aplaviroc, Vicriviroc, Bevirimat, Elvitegravir, or raltegravir. 18. The method of claim 12, wherein the method further comprises administering the compound to the subject in combination or alternation with an anti-HBV agent. 19. The method of claim 18, wherein the anti-HBV agent is entecavir, lamivudine, interferon alfa-2b, peginterferon alfa-2a, adefovir dipivoxil, telbivudine, emtricitibine, clevudine, tenofovir, valtorcitabine, amdoxovir, remofovir, or racivir. 20. The method of claim 12, wherein the compound is administered orally. 21. The method of claim 20, wherein the compound is administered orally once per day. 22. The method of claim 12, wherein the compound is administered in combination with a second compound effective for the treatment or prevention of HCV infection in the subject. |
Details for Patent 8,486,991
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2026-09-29 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2026-09-29 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2026-09-29 | |
Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 10/16/2002 | ⤷ Try a Trial | 2026-09-29 |
Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 01/07/2004 | ⤷ Try a Trial | 2026-09-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.